Key terms
About BCAB
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BCAB news
Mar 27
6:10am ET
BioAtla price target lowered to $7 from $10 at H.C. Wainwright
Mar 26
4:32pm ET
BioAtla reports Q4 revenue $7.8M vs $5.8M last year
Mar 26
4:06pm ET
BioAtla reports Q4 net loss $26.9M vs. $27.6M last year
Feb 21
4:14pm ET
BioAtla Rewards Executives for Meeting Performance Goals
Feb 12
4:13pm ET
BioAtla Faces Class Action Lawsuit Over Bylaw Provisions
Jan 23
8:25am ET
Strong Buy for BioAtla: Promising ADC Developments and Strategic Oncology Pipeline
Jan 10
7:17am ET
Buy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical Trials
Jan 07
5:27am ET
BioAtla (BCAB) Gets a Buy from BTIG
Jan 02
9:09am ET
BTIG Keeps Their Buy Rating on BioAtla (BCAB)
Dec 31
5:07am ET
BTIG Keeps Their Buy Rating on BioAtla (BCAB)
No recent press releases are available for BCAB
BCAB Financials
Key terms
Ad Feedback
BCAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BCAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
